News

The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with malignant

The priority review has been specifically designated for treatment of FL patients whose disease had relapsed or is in the refractory stage and had also received at least

The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share

The Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules. Commissioner Margrethe Vestager, in charge of competition policy, said: "When

PhaseOut DMD aims to provide proof of concept for ezutromid through measures of a number of endpoints related to muscle structure, health and function. The Company believes the

The research was recently published in Nature Communications. In the case of cancer treatment, to target specific tumors in the body, scientists have developed techniques where drug molecules

The company will start a tender offer to purchase all of the issued and outstanding shares of Patheon for $35.00 per share in cash. Patheon is a pharmaceutical

Tenapanor is Ardelyx's investigational, minimally systemic, small-molecule NHE3 inhibitor. The T3MPO-1 trial achieved statistical significance for the primary endpoint and seven of eight secondary endpoints. The primary endpoint,

"The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this